Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial-Reference-Cited by-同舟云学术

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Published:2022-05 Issue:10340 Volume:399 Page:2031-2046
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ferrante Marc,Panaccione Remo,Baert Filip,Bossuyt Peter,Colombel Jean-Frederic,Danese Silvio,Dubinsky Marla,Feagan Brian G,Hisamatsu Tadakazu,Lim Allen,Lindsay James O,Loftus Edward V,Panés Julián,Peyrin-Biroulet Laurent,Ran Zhihua,Rubin David T,Sandborn William J,Schreiber Stefan,Neimark Ezequiel,Song Alexandra,Kligys Kristina,Pang Yinuo,Pivorunas Valerie,Berg Sofie,Duan W Rachel,Huang Bidan,Kalabic Jasmina,Liao Xiaomei,Robinson Anne,Wallace Kori,D'Haens Geert

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease;Geremia;J Exp Med,2011

2. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene;Duerr;Science,2006

3. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease;Kobayashi;Gut,2008

4. Interleukin-23: immunological roles and clinical implications;Tan;Int J Biochem Cell Biol,2009

5. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease;Schmitt;Gut,2019

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Effectiveness of risankizumab induction and maintenance therapy for refractory Crohn’s disease: a real-world experience from a preapproval access programme and early access to medicines scheme;Frontline Gastroenterology;2024-08-30

3. Efficacy and Safety of Interleukin-12/23 and Interleukin-23 Inhibitors for Ulcerative Colitis: A Systematic Review Ad Meta-Analysis of Randomized Controlled Trials;American Journal of Therapeutics;2024-08-30

4. Efficacy and Safety of Risankizumab in the Treatment of Crohn's Disease of the Pouch;ACG Case Reports Journal;2024-08-29

5. Epithelial barrier dysfunction and microbial dysbiosis: exploring the pathogenesis and therapeutic strategies for Crohn’s disease;Tissue Barriers;2024-08-26